Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiaoyun Nicole Li

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Journal of Biopharmaceutical Statistics|January 22, 2024
A win ratio-based framework to combine multiple clinical endpoints in exploratory basket trialsPingye Zhang, Xiaoyun Nicole Li
Journal of Biopharmaceutical Statistics|February 19, 2026
A simulation study comparing backfill and randomized expansion in oncology dose optimizationHuan Cheng, Xiaoyun Nicole Li
Contemporary Clinical Trials|September 29, 2022
A 2-in-1 adaptive design to seamlessly expand a selected dose from a phase 2 trial to a phase 3 trial for oncology drug developmentPingye Zhang, Xiaoyun Nicole Li, Kaifeng Lu, et al.
Contemporary Clinical Trials|July 9, 2018
Adaptive expansion of biomarker populations in phase 3 clinical trialsCong Chen, Xiaoyun Nicole Li, Wen Li, et al.
Contemporary Clinical Trials|February 21, 2023
A variation of a 2-in-1 adaptive design to seamlessly expand a selected dose from a phase 2 trial to a phase 3 trial for oncology drug developmentPingye Zhang, Xiaoyun Nicole Li, Kaifeng Lu, et al.
JCO Clinical Cancer Informatics|January 13, 2021
Overall Survival With Second-Line Pembrolizumab in Patients With Non-Small-Cell Lung Cancer: Randomized Phase III Clinical Trial Versus Propensity-Adjusted Real-World DataThomas Jemielita, Xiaoyun Nicole Li, Bilal Piperdi, et al.
JCO Clinical Cancer Informatics|August 20, 2021
Augmenting Real-World Data Through Modeling Key Clinical Trial Eligibility Criteria: An Example of Patients With Non-small-Cell Lung Cancer Treated With PembrolizumabThomas Jemielita, Xiaoyun Nicole Li, Thomas Burke, et al.
Journal of Biopharmaceutical Statistics|February 16, 2024
Considerations for master protocols using external controlsJie Chen, Xiaoyun Nicole Li, Chengxing Cindy Lu, et al.
Journal for Immunotherapy of Cancer|February 10, 2019
Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?Meihua Wang, Cong Chen, Thomas Jemielita, et al.
Therapeutic Innovation & Regulatory Science|June 23, 2021
Practical Considerations and Recommendations for Master Protocol Framework: Basket, Umbrella and Platform TrialsChengxing Cindy Lu, Xiaoyun Nicole Li, Kristine Broglio, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Journal of Biopharmaceutical Statistics|January 22, 2024
A win ratio-based framework to combine multiple clinical endpoints in exploratory basket trialsPingye Zhang, Xiaoyun Nicole Li
Journal of Biopharmaceutical Statistics|February 19, 2026
A simulation study comparing backfill and randomized expansion in oncology dose optimizationHuan Cheng, Xiaoyun Nicole Li
Contemporary Clinical Trials|September 29, 2022
A 2-in-1 adaptive design to seamlessly expand a selected dose from a phase 2 trial to a phase 3 trial for oncology drug developmentPingye Zhang, Xiaoyun Nicole Li, Kaifeng Lu, et al.
Contemporary Clinical Trials|July 9, 2018
Adaptive expansion of biomarker populations in phase 3 clinical trialsCong Chen, Xiaoyun Nicole Li, Wen Li, et al.
Contemporary Clinical Trials|February 21, 2023
A variation of a 2-in-1 adaptive design to seamlessly expand a selected dose from a phase 2 trial to a phase 3 trial for oncology drug developmentPingye Zhang, Xiaoyun Nicole Li, Kaifeng Lu, et al.
JCO Clinical Cancer Informatics|January 13, 2021
Overall Survival With Second-Line Pembrolizumab in Patients With Non-Small-Cell Lung Cancer: Randomized Phase III Clinical Trial Versus Propensity-Adjusted Real-World DataThomas Jemielita, Xiaoyun Nicole Li, Bilal Piperdi, et al.
JCO Clinical Cancer Informatics|August 20, 2021
Augmenting Real-World Data Through Modeling Key Clinical Trial Eligibility Criteria: An Example of Patients With Non-small-Cell Lung Cancer Treated With PembrolizumabThomas Jemielita, Xiaoyun Nicole Li, Thomas Burke, et al.
Journal of Biopharmaceutical Statistics|February 16, 2024
Considerations for master protocols using external controlsJie Chen, Xiaoyun Nicole Li, Chengxing Cindy Lu, et al.
Journal for Immunotherapy of Cancer|February 10, 2019
Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?Meihua Wang, Cong Chen, Thomas Jemielita, et al.
Therapeutic Innovation & Regulatory Science|June 23, 2021
Practical Considerations and Recommendations for Master Protocol Framework: Basket, Umbrella and Platform TrialsChengxing Cindy Lu, Xiaoyun Nicole Li, Kristine Broglio, et al.
Pageof 2